Skip to main content
SpringerLink
Log in

Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials?

  • Review
  • Cytokines, Gene Therapy
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Colombo MC, Musso T, Gusella L, Forni G (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNFα, GM-CSF, and IFNγ gene or admixed with conventional adjuvants. Cancer Res 54: 6022

    PubMed  Google Scholar 

  2. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143: 1283

    PubMed  Google Scholar 

  3. Boel P, Wildman C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Van der Bruggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167

    PubMed  Google Scholar 

  4. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337

    PubMed  Google Scholar 

  5. Brichard V, Van Pel A, Wolfel T, De Plaen E, Lethé B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489

    PubMed  Google Scholar 

  6. Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T (1995) Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur J Immunol 25: 664

    PubMed  Google Scholar 

  7. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP (1995) IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154: 5282

    PubMed  Google Scholar 

  8. Carbone G, Borrello MG, Molla A, Rizzetti MG, Pierotti MA, Della Porta G, Parmiani G (1991) Activation ofras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int J Cancer 47: 619

    PubMed  Google Scholar 

  9. Cascinelli N, Foà R, Parminani G, Arienti F, Belli F, Bernengo MG, Clemente C, Colombo MP, Guarini A, Illeni MT, Mascheroni L, Melani C, Prada A, Sulè-Suso J (1994) active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I–II study. Hum gene Ther 5: 1059

    PubMed  Google Scholar 

  10. Chen L, Linsley PS, Hellstrom KE (1993) Costimulation of T cells for tumor immunity. Immunol Today 14: 483–486

    PubMed  Google Scholar 

  11. Colombo MP, Modesti A, Parmiani G, Forni G (1992) Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52: 4853

    PubMed  Google Scholar 

  12. Colombo MP, Forni G (1994) Cytokine gene transfer in tumour inhibition and tentative tumour therapy. Where are we now? Immunol Today 15: 48

    PubMed  Google Scholar 

  13. Cordier L, Duffour MT, Sabourin JC, Lee MG, Cabannes J, Ragot T, Perricaudet M, Haddada H (1995) Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther 2: 16

    PubMed  Google Scholar 

  14. Coulie PG, Brichard V, Van Pel A, Wolfel T, Scheneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J, Renaul J, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180: 35

    PubMed  Google Scholar 

  15. Coulie PG, Lehman F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92: 7976

    PubMed  Google Scholar 

  16. De Bergeyck B, De Plaen E, Chomez P, Boon T, Van Pel A (1994) An intracisternal A-particle sequence codes for an antigen recognized by syngenic cytolytic T lymphocytes in a mouse spontaneous leukemia. Eur J Immunol 24: 2203

    PubMed  Google Scholar 

  17. De Plaen E, Lurquin C, Van Pel A, Mariamé B, Szikora J, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum−) variants of mouse tumor P815: cloning of the gene of tum− antigen P91A and identification of the tum− mutation. Proc Natl Acad Sci USA 85: 2274

    PubMed  Google Scholar 

  18. Estin CD, Stevenson US, Plowman GD, Hu SL, Sridhar P, Hellstrom I, Brown JP, hellstrom KE (1988) Recombinant vaccinia vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc. Natl Acad Sci USA 85: 1052

    PubMed  Google Scholar 

  19. Frassanito MA, Mayordomo JI, De Leo RM, Storkus WJ, Lotze MT, De Leo AB (1995) Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. J Immunol 55: 124

    Google Scholar 

  20. Galetto G, Law LW, Rogers MJ (1985) The Rausher-MuLV-induced leukemia, RBL-5, bears two tumor-associated transplantation antigens expressed on distinct molecules. Int J Cancer 36: 713

    PubMed  Google Scholar 

  21. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pellicci PG, Parmiani G (1993) Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyielocytic leukemia cells. Blood 5: 1369

    Google Scholar 

  22. Gaugler B, Van den Eynde B, Van der Bruggen P, Robero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma autologous cytolytic T lymphocytes. J Exp Med 179: 921

    PubMed  Google Scholar 

  23. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG (1993) Recognition of the EBV encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11 restricted cytotoxic T lymphocytes: implications for the down regulation of HLA-A11 in Burkitt's lymphoma. Proc Natl Acad Sci USA 89: 5862

    Google Scholar 

  24. Gedde-Dahl T III, Fossum B, Eriksen JA, Thorsby E, Gaudenack G (1993) T cell clones specific for p21 Ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 23: 754

    PubMed  Google Scholar 

  25. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281

    PubMed  Google Scholar 

  26. Grohmann U, Puccetti P, Belladonna ML, Fallarino F, Bianchi R, Binaglia L, Sagakuchi K, Mage MG, Appella E, Fioretti MC (1995) Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J Immunol 154: 4630

    PubMed  Google Scholar 

  27. Hock H, Dorsh M, Kunzendorf U, Quin Z, Diamanstein T, Blankenstain T (1993) Mechanisms of rejection by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Sci USA 90: 2774

    Google Scholar 

  28. Houbiers JGA, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, Van da Velte CJH, Brand A, Momburg F, Kast WM, Melief CJM (1993) In vitro induction of human cytotoxic T lymphocytes responses against peptides of mutant and wild-type p53. Eur J Immunol 23: 2072

    PubMed  Google Scholar 

  29. Huang YC, Golumbeck P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone-marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961

    PubMed  Google Scholar 

  30. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151: 3693

    PubMed  Google Scholar 

  31. Kast WM, Brandt RM, Drijfhout JW, Melief CJ (1993) Human leukocyte antigen-A2.1 candidate cytotoxic T lymphocytes epitopes of human papillomavirus type 16E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14: 115

    PubMed  Google Scholar 

  32. Kawakami Y, Eliyahu S, Delgado C, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515

    PubMed  Google Scholar 

  33. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Scad Sci USA 90: 4942

    Google Scholar 

  34. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Frabetti F, Cavallo F, Giovarelli M, Forni G, Modica A, Modesti A, Musiani P, Nanni P (1995) Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer γ-interferon in the same cell. Efficient MHC expression and inhibition of tumor and metastasis growth. Hum Gene Ther 6: 743

    PubMed  Google Scholar 

  35. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67

    PubMed  Google Scholar 

  36. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G, Colombo MP (1995) CD4 T cells inhibits in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur J Immunol 25: 137

    PubMed  Google Scholar 

  37. Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP (1994) Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell response and prolongs survival of thymomabearing mice. Cancer Res 54: 4155

    PubMed  Google Scholar 

  38. Mitsuya H, Matis LA, Megson M, Bunn PA, Murray C, Mann DL, Gallo RC, Broder S (1983) Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 158: 994

    PubMed  Google Scholar 

  39. Monach PA, Meredith SC, Siegel CT, Schreiber H (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2: 45

    PubMed  Google Scholar 

  40. Nabel EG, Yang Z, Muller D, Chang AE, Gao X, Huang GL, Cho KJ, Nabel GJ (1994) Safety and toxicity of cathether gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 5: 1089

    PubMed  Google Scholar 

  41. Nabel GJ, Nabel EG, Yang Z, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA liposome complexes in melanoma expression, biological activity and lack of toxicity in humans. Proc Natl Acad Sci USA 90: 11307

    PubMed  Google Scholar 

  42. Nathan C, Sporn MJ (1991) Cytokines in the context. J Cell Biol 113: 981

    PubMed  Google Scholar 

  43. Noguchi Y, Chen Y, Old LJ (1994) A mouse mutant p53 product recognized by CD4 and CD8 T cells. Proc Natl Acad Sci USA 91: 3171

    PubMed  Google Scholar 

  44. Osanto S, Brouwenstyn N, Vaessen N, et al (1993) Immunization with interleukin-2 transfected melanoma cells. A phase I–II study in patients with metastatic melanoma. Hum Gene Ther 4: 323

    PubMed  Google Scholar 

  45. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med (in press)

  46. Peace DJ, Smith JW, Chen W, You S-G, Cosand W-L, Blake J, Cheever MA (1994) Lysis ofras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptides. J Exp Med 179: 473

    PubMed  Google Scholar 

  47. Pedrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H (1990) Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med 171: 1205–1220

    PubMed  Google Scholar 

  48. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA (1995) CD4+ T-cell immunity to mutatedras protein in pancreatic and colon cancer patients. Cancer Res 55: 2984

    PubMed  Google Scholar 

  49. Ramquist T, Pallas DO, Deanda J, Ahrund-Richter L, Reinholdsson G, Roberts TM, Schaffausen BS, Dalianis T (1988) Immunization against the polyoma tumor-specific transplantation antigen (TSTA) with polyoma T antigen. Int J Cancer 42: 123

    PubMed  Google Scholar 

  50. Rashid HU, Barsoum AL, Coggin JH (1994) Identification of partial complementary DNA clones encoding a 59-kd protein with characteristics of a unique oncofetal antigen. J Natl Cancer Inst 86: 515

    PubMed  Google Scholar 

  51. Sibille C, Chomez P, Wildmann C, Van Pel A, De Pael E, Maryanski JL, De Bergeyck V, Boon T (1990) Structure of the gene of tum− transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 172: 35

    PubMed  Google Scholar 

  52. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H (1992) Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175: 139–146

    PubMed  Google Scholar 

  53. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP (1993) Regression of an established tumor genetically modified to release G-CSF requires granulocyte-T cell cooperation and T cell-produced IFNγ. J Exp Med 178: 151

    PubMed  Google Scholar 

  54. Szikora JP, Van Pel A, Brichard V, André M, Van Baren N, Henry P, De Pael E, Boon T (1990) Structure of the gene of tum− transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J 9: 1041

    PubMed  Google Scholar 

  55. Tanaka Y, Tevethia MJ, Kalderon D, Smith AE, Tevethia SS (1988) Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology 162: 427

    PubMed  Google Scholar 

  56. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 82

    Google Scholar 

  57. Udono H, Srivastava P (1994) Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 152: 5398

    PubMed  Google Scholar 

  58. Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E (1994) Identification of a unique antigen peptide pRL1 on BALB/c RL01 leukemia recognized by cytotoxic T lymphocytes and its relation to theakt oncogene. J Exp Med 180: 1599

    PubMed  Google Scholar 

  59. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene encoding a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373

    PubMed  Google Scholar 

  60. Van der Bruggen P, Traversari C, Chomez P, Lurquin E, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643

    PubMed  Google Scholar 

  61. Vieweg J, Bockzowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, Gilboa E (1995) Efficient gene transfer with adeno-associated virus-based plasmid complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55: 2366

    PubMed  Google Scholar 

  62. Wettstein PJ (1986) Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 24: 24

    PubMed  Google Scholar 

  63. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmanhieb E, De Plaen E, Hankeln T, Zum Buschenfelde KM, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281

    PubMed  Google Scholar 

  64. Yoshino I, Peoples GE, Godegebuure PS, Maziarz R, Eberlein TJ (1994) Association ofHER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152: 2393

    PubMed  Google Scholar 

  65. Zatloukal K, Scheeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 154: 3406

    PubMed  Google Scholar 

  66. Zhao X, Cheung NV (1995) GD2 oligosaccaride: target for cytotoxic T lymphocytes. J Exp Med 182: 67

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Oncology D and Gene Therapy Program, Istituto Nazionale Tumori, Via G. Venezian 1, 20133, Milano, Italy

    Mario P. Colombo & Monica Rodolfo

Authors
  1. Mario P. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Rodolfo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colombo, M.P., Rodolfo, M. Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials?. Cancer Immunol Immunother 41, 265–270 (1995). https://doi.org/10.1007/BF01517213

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01517213

Keywords

Search

Navigation